Bioventus Inc (BVS)

$4.7

+0.06

(+1.29%)▲

Market is closed - opens 7 PM, 18 Apr 2024

Insights on Bioventus Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 120.79M → 135.42M (in $), with an average increase of 10.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -7.30M → -6.09M (in $), with an average increase of 19.8% per quarter

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 134.4%

Performance

  • $4.57
    $4.86
    $4.70
    downward going graph

    2.83%

    Downside

    Day's Volatility :6.03%

    Upside

    3.29%

    downward going graph
  • $0.86
    $6.08
    $4.70
    downward going graph

    81.7%

    Downside

    52 Weeks Volatility :85.86%

    Upside

    22.7%

    downward going graph

Returns

PeriodBioventus IncSector (Health Care)Index (Russel 2000)
3 Months
-1.67%
-0.7%
0.0%
6 Months
56.67%
6.6%
0.0%
1 Year
343.4%
3.7%
-1.5%
3 Years
-68.2%
14.0%
-21.8%

Highlights

Market Capitalization
294.1M
Book Value
$2.74
Earnings Per Share (EPS)
-1.54
PEG Ratio
2.14
Wall Street Target Price
8.0
Profit Margin
-30.49%
Operating Margin TTM
1.91%
Return On Assets TTM
0.12%
Return On Equity TTM
-38.27%
Revenue TTM
512.3M
Revenue Per Share TTM
8.18
Quarterly Revenue Growth YOY
7.6%
Gross Profit TTM
302.7M
EBITDA
28.8M
Diluted Eps TTM
-1.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.16
EPS Estimate Next Year
0.38
EPS Estimate Current Quarter
0.02
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    10%Buy
    30%Hold
    60%Sell
Based on 10 Wall street analysts offering stock ratings for Bioventus Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
00
Hold
3
3
4
Sell
6
6
6

Analyst Forecast

What analysts predicted

Upside of 70.21%

Current $4.70
Target $8.00

Company Financials

FY18Y/Y Change
Revenue
319.2M
↑ 25.83%
Net Income
-12.2M
↓ 64.21%
Net Profit Margin
-3.82%
↑ 9.63%
FY19Y/Y Change
Revenue
340.1M
↑ 6.57%
Net Income
6.9M
↓ 156.12%
Net Profit Margin
2.01%
↑ 5.83%
FY20Y/Y Change
Revenue
321.2M
↓ 5.58%
Net Income
16.4M
↑ 139.54%
Net Profit Margin
5.11%
↑ 3.1%
FY21Y/Y Change
Revenue
430.9M
↑ 34.17%
Net Income
9.6M
↓ 41.59%
Net Profit Margin
2.22%
↓ 2.89%
FY22Y/Y Change
Revenue
512.1M
↑ 18.85%
Net Income
-213.4M
↓ 2326.07%
Net Profit Margin
-41.67%
↓ 43.89%
FY23Y/Y Change
Revenue
512.3M
↑ 0.04%
Net Income
-156.2M
↓ 26.79%
Net Profit Margin
-30.49%
↑ 11.18%
Q3 FY22Q/Q Change
Revenue
137.1M
↓ 2.32%
Net Income
3.2M
↓ 139.62%
Net Profit Margin
2.32%
↑ 8.03%
Q4 FY22Q/Q Change
Revenue
125.8M
↓ 8.2%
Net Income
-44.9M
↓ 1513.32%
Net Profit Margin
-35.66%
↓ 37.98%
Q1 FY23Q/Q Change
Revenue
119.1M
↓ 5.38%
Net Income
-100.0M
↑ 122.89%
Net Profit Margin
-84.01%
↓ 48.35%
Q2 FY23Q/Q Change
Revenue
137.1M
↑ 15.13%
Net Income
-3.7M
↓ 96.32%
Net Profit Margin
-2.69%
↑ 81.32%
Q3 FY23Q/Q Change
Revenue
120.8M
↓ 11.87%
Net Income
-7.3M
↑ 98.4%
Net Profit Margin
-6.05%
↓ 3.36%
Q4 FY23Q/Q Change
Revenue
135.4M
↑ 12.11%
Net Income
-6.1M
↓ 16.53%
Net Profit Margin
-4.5%
↑ 1.55%
FY18Y/Y Change
Total Assets
442.7M
↓ 9.16%
Total Liabilities
297.5M
↑ 0.83%
FY19Y/Y Change
Total Assets
472.4M
↑ 6.7%
Total Liabilities
326.8M
↑ 9.86%
FY20Y/Y Change
Total Assets
494.5M
↑ 4.67%
Total Liabilities
350.3M
↑ 7.2%
FY21Y/Y Change
Total Assets
1.2B
↑ 147.92%
Total Liabilities
692.1M
↑ 97.56%
FY22Y/Y Change
Total Assets
1.4B
↑ 11.97%
Total Liabilities
1.0B
↑ 49.16%
FY23Y/Y Change
Total Assets
810.9M
↓ 40.92%
Total Liabilities
589.8M
↓ 42.87%
Q3 FY22Q/Q Change
Total Assets
1.6B
↑ 31.31%
Total Liabilities
1.1B
↑ 53.82%
Q4 FY22Q/Q Change
Total Assets
1.4B
↓ 13.52%
Total Liabilities
1.0B
↓ 2.54%
Q1 FY23Q/Q Change
Total Assets
887.4M
↓ 35.35%
Total Liabilities
647.0M
↓ 37.32%
Q2 FY23Q/Q Change
Total Assets
837.0M
↓ 5.68%
Total Liabilities
603.6M
↓ 6.71%
Q3 FY23Q/Q Change
Total Assets
811.1M
↓ 3.09%
Total Liabilities
584.6M
↓ 3.14%
Q4 FY23Q/Q Change
Total Assets
810.9M
↓ 0.02%
Total Liabilities
589.8M
↑ 0.88%
FY18Y/Y Change
Operating Cash Flow
45.2M
↑ 138.83%
Investing Cash Flow
-6.1M
↓ 89.86%
Financing Cash Flow
-13.3M
↓ 142.42%
FY19Y/Y Change
Operating Cash Flow
40.7M
↓ 9.9%
Investing Cash Flow
-7.9M
↑ 29.68%
Financing Cash Flow
-11.0M
↓ 17.39%
FY20Y/Y Change
Operating Cash Flow
71.8M
↑ 76.35%
Investing Cash Flow
-20.5M
↑ 159.1%
Financing Cash Flow
-29.6M
↑ 170.01%
FY21Y/Y Change
Operating Cash Flow
23.0M
↓ 67.98%
Investing Cash Flow
-283.8M
↑ 1284.2%
Financing Cash Flow
273.4M
↓ 1024.52%
Q3 FY22Q/Q Change
Operating Cash Flow
-701.0K
↓ 123.85%
Investing Cash Flow
-56.3M
↑ 8.28%
Financing Cash Flow
50.7M
↑ 561.71%
Q4 FY22Q/Q Change
Operating Cash Flow
5.2M
↓ 848.07%
Investing Cash Flow
33.5M
↓ 159.47%
Financing Cash Flow
-5.4M
↓ 110.74%
Q1 FY23Q/Q Change
Operating Cash Flow
2.5M
↓ 52.52%
Investing Cash Flow
-15.1M
↓ 144.97%
Financing Cash Flow
27.4M
↓ 603.49%
Q2 FY23Q/Q Change
Operating Cash Flow
10.8M
↑ 333.53%
Investing Cash Flow
33.5M
↓ 322.35%
Financing Cash Flow
-62.2M
↓ 327.35%

Technicals Summary

Sell

Neutral

Buy

Bioventus Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bioventus Inc
Bioventus Inc
-14.39%
56.67%
343.4%
-68.2%
-75.53%
Stryker Corporation
Stryker Corporation
-5.1%
24.37%
15.51%
30.88%
86.41%
Boston Scientific Corp.
Boston Scientific Corp.
1.07%
34.02%
31.68%
66.24%
93.56%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-6.04%
25.15%
3.43%
-1.49%
47.65%
Abbott Laboratories
Abbott Laboratories
-5.82%
10.82%
1.68%
-14.96%
43.26%
Medtronic Plc
Medtronic Plc
-5.47%
8.78%
-3.15%
-37.3%
-6.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bioventus Inc
Bioventus Inc
9.44
NA
2.14
0.16
-0.38
0.0
NA
2.74
Stryker Corporation
Stryker Corporation
40.98
40.98
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.66
63.66
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
39.15
39.15
5.19
2.76
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.4
33.4
5.99
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.16
25.16
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bioventus Inc
Bioventus Inc
Sell
$294.1M
-75.53%
9.44
-30.49%
Stryker Corporation
Stryker Corporation
Buy
$128.5B
86.41%
40.98
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.1B
93.56%
63.66
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.2B
47.65%
39.15
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$189.5B
43.26%
33.4
14.27%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-6.1%
25.16
13.0%

Institutional Holdings

  • Essex Woodlands Health Ventures

    16.45%

  • Nantahala Capital Management, LLC

    15.10%

  • Juniper Investment Co, LLC

    8.63%

  • Vanguard Group Inc

    1.54%

  • Kent Lake Capital LLC

    0.67%

  • BlackRock Inc

    0.64%

Company Information

bioventus® is a global leader in orthobiologics and its mission is to make a difference by helping patients resume and enjoy active lives. bioventus accomplishes this with its orthobiologic products for musculoskeletal healing, regeneration and related biosurgery that engage and enhance the body’s natural healing processes. the company has two product portfolios for orthobiologics, bioventus active healing therapies and bioventus surgical, which are created through a combination of internal product development, product/business acquisition, and distribution agreements. established in 2012, bioventus is privately held and headquartered in durham, nc. the company has nearly 600 employees worldwide and its international headquarters is in hoofddorp, the netherlands. bioventus also has offices in memphis, tn, australia and canada, and a research and development site is located in boston. bioventus works with patients, payers and health care providers throughout the world, and generat

Organization
Bioventus Inc
Employees
970
CEO
Mr. Mark L. Singleton
Industry
Healthcare

Discover More

FAQs